Concepedia

Michael Stanglmaier

MS

Statistics

Publications

7

Citations

525

H-Index

7

Active since

2002

Affiliations

LMU Klinikum(Current)

Helmholtz Zentrum München

Pharmalog (Germany)

Ludwig-Maximilians-Universität München

Michael Stanglmaier is an author at LMU Klinikum specializing in cancer immunotherapy, oncology, and immunology.

Publications per year

2002–2014

7

Publications

7

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

Zoltan A. Nagy, Bernd Hubner, Corinna Löhning et al. · Nature Medicine · 2002 · 142 citations

, , +16

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

Michael Stanglmaier, Simone Reis, Michael Hallek · Annals of Hematology · 2004 · 120 citations

, , +16

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

Michael Stanglmaier, Markus Warmuth, I Kleinlein et al. · Leukemia · 2003 · 81 citations

, , +14

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

Michael Stanglmaier, M. Faltin, Peter Ruf et al. · International Journal of Cancer · 2008 · 66 citations · Full text

, , +17

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Raymund Buhmann, Belinda Pinto Simões, Michael Stanglmaier et al. · Bone Marrow Transplantation · 2008 · 49 citations

, , +16

1–5 of 7